26 results
8-K
EX-99.1
BHVN
Biohaven Ltd.
9 May 24
Biohaven Reports First Quarter 2024 Financial Results and Recent Business Developments
4:14pm
for the potential treatment of dilated cardiomyopathy and galactose deficient IgA for IgA nephropathy."
Dr. Coric continued, “The Biohaven R&D team continues … development plans and research efforts. We look forward to unveiling further updates across our clinical programs and future development plans at our annual R&D Day
8-K
EX-99.1
BHVN
Biohaven Ltd.
15 Apr 24
Regulation FD Disclosure
6:59am
updates planned at the Company’s R&D Day on May 29, 2024 STATUS: 16 Subjects Completed Two Dosing Cohorts to Date Sentinel dosing paradigm: 1 sentinel
8-K
EX-99.1
BHVN
Biohaven Ltd.
29 Feb 24
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
4:16pm
million of restricted cash.
Fourth Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share … became a standalone public company.
R&D Expenses: R&D expenses, including non-cash share-based compensation, were $373.3 million for the year ended
8-K
EX-99.1
guhapwqgxqmed4km
14 Nov 23
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
4:26pm
8-K
EX-99.1
349oe x6uy4du4
31 Jul 23
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
4:29pm
8-K
EX-99.1
he5q8i 6behabn2vpl
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
8-K
u4u0irre
31 May 23
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
7:03am
8-K
EX-99.1
odiyvornhqeng1r
12 May 23
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
4:47pm
10-Q
x12 iq5hw
9 Nov 22
Quarterly report
4:19pm
8-K
EX-99.1
u8rv rlhe3hh06
9 Nov 22
Biohaven LTD. Reports Third Quarter 2022 Financial Results and Reports Recent Business Developments
4:05pm
424B4
i8i12jc
24 Oct 22
Prospectus supplement with pricing info
9:38am
S-1/A
h65gwxbkoy fve
20 Oct 22
IPO registration (amended)
10:00am
S-1
4d6dbix83
18 Oct 22
IPO registration
4:03pm
DRS
yy01b
11 Oct 22
Draft registration statement
12:00am